Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports US$ 25.55 Min. order: 1 piece ★★★★★ 4.2 (267 reviews) Sold : Login>>
Pressure rises on Novo as Innovent drug tops Ozempic US$ 27.02 Min. order: 1 piece ★★★★★ 5.0 (253 reviews) Sold : Login>>
What is the pipeline for future medications for obesity? US$ 29.39 Min. order: 1 piece ★★★★★ 4.4 (290 reviews) Sold : Login>>
New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists US$ 23.73 Min. order: 1 piece ★★★★★ 4.8 (282 reviews) Sold : Login>>